Physician profile
Ricardo H Alvarez
NPI 1649441601
$552,526.13
in general payments reported to CMS, 2019-2025
79 companies · $150K in 2025
The $150K reported for 2025 was more than what 99% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $34K · 2021: $43K · 2022: $79K · 2023: $118K · 2024: $95K · 2025: $150K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $280K · Travel and Lodging: $59K · Consulting Fee: $13K · Food and Beverage: $11K · Honoraria: $266 · Grant: $250 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $279,915.00 |
| Travel and Lodging | $58,654.70 |
| Consulting Fee | $13,143.75 |
| Food and Beverage | $10,540.97 |
| Honoraria | $265.64 |
| Grant | $250.00 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $274,653.31 | 2021-2025 | Trodelvy |
| Stemline Therapeutics INC. | $112,786.15 | 2022-2025 | Orserdu |
| Astrazeneca Pharmaceuticals Lp | $46,963.30 | 2019-2025 | Enhertu, Datroway, Lynparza |
| Eisai INC. | $32,827.82 | 2019-2025 | |
| Daiichi Sankyo INC. | $24,802.33 | 2019-2025 | Enhertu, Datroway |
| Puma Biotechnology, INC. | $23,280.09 | 2019-2025 | Nerlynx |
| Novartis Pharmaceuticals Corporation | $15,743.26 | 2019-2025 | Kisqali |
| R-Pharm US LLC | $7,579.31 | 2019-2020 | |
| Immunomedics, INC. | $3,638.17 | 2020 | |
| Heron Therapeutics, INC. | $2,050.00 | 2019 | |
| Pfizer INC. | $1,924.87 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $637.36 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $598.99 | 2019-2025 | Erleada, Akeega, Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $503.54 | 2019-2025 | Opdivo, Opdualag |
| Celgene Corporation | $486.90 | 2020-2025 | Pomalyst, Reblozyl, Opdualag |
Show all 70 companies
9 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricardo Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.